# Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction

> **NCT07082816** · PHASE3 · COMPLETED · sponsor: **Alcon Research** · enrollment: 489 (actual)

## Conditions studied

- Ocular Hypertension
- Open Angle Glaucoma

## Interventions

- **DRUG:** Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution
- **DRUG:** Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution

## Key facts

- **NCT ID:** NCT07082816
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-09-02
- **Primary completion:** 2026-04-06
- **Final completion:** 2026-04-06
- **Target enrollment:** 489 (ACTUAL)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07082816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07082816, "Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT07082816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*